BOAST - Management of Metastatic Bone Disease
Last Updated: June 2022
Date Published: June 2022
BOAST Management of Metastatic Bone Disease
Background and justification
Patients presenting with suspected MBD should be managed along a defined pathway from presentation to rehabilitation. Low energy fractures in the non-osteoporotic population, antecedent pain, night pain, absence of injury, and insidious pain are suspicious for underlying malignancy.
Inclusions:
Suspected MBD of the appendicular skeleton, pelvis and scapula.
Exclusions:
Osteoporotic or stress fractures. Spinal metastases.
Standards for Practice
- Each unit should have an agreed policy for the multidisciplinary discussion and management of MBD including clear pathways for onward referral.
- All specialist centres should have agreed pathways to enable prompt opinion, advice, and transfers within their network.
- Prodromal pain, history of malignancy, or night pain raise suspicion of MBD and should be documented along with any circumstances of injury.
- A patient with radiographic features of a primary bone tumour, including bone destruction, new bone formation, periosteal reaction, or soft-tissue swelling should be referred to a bone sarcoma centre* within 72 hours#.
- Biopsy of a suspected primary bone tumour must be performed at a bone sarcoma centre.
- The following investigations should be conducted when MBD is suspected:
- FBC, U+E, LFT, calcium & bone profile, PSA in men, myeloma screen.
- Orthogonal radiographs of the whole bone
- Staging CT of the thorax, abdomen and pelvis (CT-TAP) within 24 hours of orthopaedic assessment
- A CT-TAP without evidence of malignancy may indicate a primary bone tumour and requires referral to a bone sarcoma
centre within 72 hours#. - MBD without an obvious primary site, should be discussed with the local acute oncology service.
- Referral to a recognised tertiary centre** is required for patients with a solitary bone metastasis.
- Multidisciplinary decisions on the use of (neo)adjuvant therapy should be recorded prior to surgery.
- Surgery for MBD should be consultant led.
- Surgical interventions should outlast the lifetime of the patient. Where internal fixation is used, curettage and cement
augmentation is recommended to replace bone loss. All patients require a construct to allow immediate weight-bearing. - All patients require thromboprophylaxis. Contraindications must be documented.
- Patients should continue under orthopaedic surveillance if they have ongoing pain. This may indicate disease
progression and/or impending failure of the reconstruction. - Failed MBD surgical intervention must be discussed with a recognised tertiary centre.
- Decisions regarding adjuvant therapy, rehabilitation and/or palliation should involve the patient, their family, and carers.
*Bone Sarcoma Centre – a specialised commissioned service for the management of bone sarcoma
**Recognised Tertiary Centre – a unit managing complex MBD with appropriate multidisciplinary capabilities
# - 72 hours is time from first suspicious or diagnostic imaging.